Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:57:02.885Z.
Calculation as of: 2026-10-06T15:57:02.885Z.
Quote observation: 2026-10-06T15:54:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0dc40ddd6b0c815ea8fb06d6c0f10798674f4babd9a38c246e46e89e51900236
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$48.27M
Price/OCF Ratio
N/A
TTM Avg
73.59
3Y Avg
628.92
5Y Avg
487.62
Market Cap
$50.81M
Price/OCF Ratio
N/A
TTM Avg
13.21
3Y Avg
14.20
5Y Avg
14.20
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lite Strategy, Inc. (LITS) | $48.68M | N/A | N/A | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $48.27M | N/A | 73.59 | 628.92 | 487.62 |
| Apollomics, Inc. (APLM)vs › | $49.85M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $49.93M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $50.28M | 2.06 | 2.08 | 4.49 | 3.97 |
| Microbot Medical Inc. (MBOT)vs › | $50.81M | N/A | 13.21 | 14.20 | 14.20 |
| Clene Inc. (CLNN)vs › | $51.09M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.18M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.34M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.36M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
